Plasma natriuretic peptide levels and the risk of cardiovascular events and death.

By Thomas J. Wang, Martin G. Larson, Daniel Levy, Emelia J. Benjamin, E. Leip, T. Omland, P. Wolf, Ramachandran S. Vasan. New England Journal of Medicine, 2004

1,425 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/3e848971528b6c91761147d0b3081ad5c8a55cf1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. Ramachandran S. Vasan
3. Daniel Levy
4. Michael J. Pencina
5. Martin G. Larson
6. J. Cleland
7. Gerasimos Filippatos
8. E. Braunwald

Citations in the corpus

• State of the art: Using natriuretic peptide levels in clinical practice (2008, background): “found that BNP levels independently predicted mortality, heart failure, stroke or transient ischaemic attack, and atrial fibrillation, even after adjusting for traditional risk factors [110].”
• 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. (2014, neutral): “Increased CRP (60, 61) Increased BNP (62, 63) AF indicates atrial fibrillation; BNP , B-type natriuretic peptide; CRP, C-reactive protein; HF, heart failure; LA, left atrial; LV, left ventricular; LVH, left ventricular hypertrophy; MI, myocardial infarction; and VHD, valvular heart disease.”
• Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart Failure in the Community (2012, methodology): “B-type natriuretic peptide (BNP) was previously measured (15).”